Pasireotide for the prevention of pancreatic fistula after pancreatoduodenectomy: comparison with a historical cohort

Background: Pasireotide, a somatostatin analogue, aims to reduce the risk of pancreatic fistula after pancreatoduodenectomy. Based on a reduced fistula rate (9 vs. 21%, p=0.006) in a randomized trial, we started the use of postoperative pasireotide twice daily for 7 days after pancreatoduodenectomy. Methods: All consecutive patients who underwent pancreatoduodenectomy from 2012 to 2018 were analyzed. Transition to pasireotide was in February...